Tango Appoints Robert Azelby To Board Of Directors

June 23, 2026 — 06:03 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - Tango Therapeutics, Inc. (TNGX), a clinical-stage biotechnology company, announced the appointment of Robert Azelby to its Board of Directors.

Azelby brings more than 30 years of experience in executive management, commercial product launches, and corporate governance. He currently serves on the Boards of ADC Therapeutics, Autolus Therapeutics, and Cardinal Health, Inc.

Previously, Azelby served as President and Chief Executive Officer of Eliem Therapeutics. He also served as CEO and board member of Alder BioPharmaceuticals from 2018 to 2019.

Tango is presently advancing its investigational PRMT5 inhibitor, Vopimetostat, through late-stage development for patients with pancreatic cancer.

TNGX closed Monday's trade at $28.50, up 1.89%. In the pre-market, shares are trading at $28.49, down 0.04%

For more such biotechstock news visit rttnews.com.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Tango Appoints Robert Azelby To Board Of Directors

Tags

Latest Articles